Evrópusambandið - íslenska - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - blóðþurrðandi lyf - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hinsveiflur og heilahimnubólur og hliðstæður - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - melatoninum inn - forðatafla - 2 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

eql pharma ab - clindamycinum hýdróklóríð - hart hylki - 150 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf.* - rivaroxabanum inn - filmuhúðuð tafla - 10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

le vet beheer b.v. - chlorphenamine maleate - stungulyf, lausn - 10 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

eql pharma ab - clindamycinum hýdróklóríð - hart hylki - 300 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

chiesi farmaceutici s.p.a.* - fosfólípíð og prótein úr svínalungum - dreifa til íkomu í barka og lungu - 80 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - levonorgestrelum inn; ethinylestradiolum inn - húðuð tafla - 150 míkróg/30 míkróg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab - human fibrinogen; human factor xiii; bovine aprotinin; human thrombin; calcii chloridum; thrombin; protein - lausnir fyrir vefjalím